Defactinib 10 mg | 99.80%
TargetMol
Defactinib is an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities.
More Information Supplier PageDefactinib
Search Results
K02288 25 mg | 99.27%
TargetMol
K02288
K02288 10 mg | 99.27%
TargetMol
K02288
BAY 11-7082 5 mg | 97.91%
TargetMol
BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
More Information Supplier PageBAY 11-7082
BAY 11-7082 50 mg | 97.91%
TargetMol
BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
More Information Supplier PageBAY 11-7082
BAY 11-7082 10 mg | 97.91%
TargetMol
BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
More Information Supplier PageBAY 11-7082
BAY 11-7082 100 mg | 97.91%
TargetMol
BAY 11-7082, a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21.
More Information Supplier PageBAY 11-7082
Des(benzylpyridyl) Atazanavi 5 mg | 98.00%
TargetMol
The N-dealkylated metabolite (M1) of Atazanavir, a HIV protease inhibitor.
More Information Supplier PageDes(benzylpyridyl) Atazanavi
K02288 50 mg | 99.27%
TargetMol
K02288
K02288 5 mg | 99.27%
TargetMol
K02288